Latest news

Achilles Therapeutics plc (NASDAQ: ACHL) announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or cNeT, manufactured with the Company's higher-dose VELOS™ Process 2 in the ongoing Phase I/IIa CHIRON clinical trial for the treatment of advanced non-small cell lung can

Gainers

  During Thursday, 849 stocks hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.

Gainers

    On Friday, 368 stocks hit new 52-week lows.

Achilles Therapeutics (NASDAQ:ACHL) reported quarterly losses of $(0.45) per share. This is a 95.17 percent increase over losses of $(9.32) per share from the same period last year.

    On Friday, 209 companies set new 52-week lows.

  During Friday's session, 445 companies made new 52-week lows.

Achilles Therapeutics (NASDAQ:ACHL) reported quarterly losses of $(0.34) per share.